Principal Financial Data
(millions of yen)
|Net sales / Sales revenue||101,448||114,716||116,637||121,885||137,547||134,000|
|Net income attributable to owners of the parent / Profit attributable to owners of the parent||12,953||16,302||16,866||20,702||23,044||21,500|
|Depreciation and amortization||2,773||3,418||3,468||3,550||2,933||5,200|
* We have voluntarily applied International Financial Reporting Standards (IFRS) to the consolidated financial statement in our annual securities report since the fiscal year ended March 2022. Therefore, our consolidated financial forecast for the fiscal year ending March 2023 is produced according to IFRS.
For the fiscal year ended March 2022, net sales were 137,547 million yen, an increase of 12.8% year on year. Factors that contributed to the increase include royalty income from overseas sales of Uptravi, a treatment for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), growth in domestic sales of new pharmaceutical products, and income from the sale of priority review vouchers issued by the U.S. Food and Drug Administration (FDA).
Net income attributable to owners of the parent
Operating income was 28,299 million yen, an 8.3% increase year on year, and net income attributable to owners of the parent was 23,044 million yen, an 11.3% increase year on year, mainly due to a decrease in the ratio of cost to sales caused by the increase in sales and improvement of the sales mix.
Principal Financial Indicators
|Fiscal year (yen)||2018/3||2019/3||2020/3||2021/3||2022/3|
|Earnings per share (EPS)||192.31||242.04||250.42||307.37||342.14|
|Dividend per share||52||70||86||99||110|
|Return on equity (ROE)||10.8||12.5||12.0||13.5||13.6|
EPS / ROE
- Earnings per share (EPS)
- Return on equity (ROE)
Dividend per share / Payout ratio
- Dividend per share
- Payout ratio
|Fiscal year (millions of yen)||2018/3||2019/3||2020/3||2021/3||2022/3|
|Cash flow from operating activities||6,719||15,310||12,737||21,388||16,018|
|Cash flow from investing activities||△11,342||511||△2,339||△1,564||△6,359|
|Cash flow from financing activities||△3,787||△3,708||△5,660||△6,199||△6,801|
Long-term Chronological Data
View long-term chronological data from here.